Relapsed/Refractory Myelofibrosis clinical trials at UCSF

• A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

  open to eligible people ages 18 years and up

  This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients with advanced cancers who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT543.

  San Francisco, California and other locations

Last updated: April 30, 2021